Lexeo is a clinical-stage genetic medicine company based in New York City, focused on reshaping heart health through pioneering gene therapy research. We're taking aim at the underlying genetic causes of cardiovascular diseases by delivering functional copies of genes directly to the heart, with the goal of providing lasting, potentially disease-curing solutions. Our pipeline targets conditions like Friedreich's ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and APOE4-associated Alzheimer's disease, building on groundbreaking research from Weill Cornell Medicine and UC San Diego.
What drives us is the opportunity to transform healthcare for people living with genetic diseases. We partner with preeminent institutions on the cutting edge of gene therapy research, using a stepwise development approach that leverages early proof-of-concept data. Our team consists of pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing, and commercialization. By targeting the root cause rather than just managing symptoms, we seek to reduce the overwhelming burden placed on patients, caregivers, and healthcare systems, and create a world where genetic medicines resolve the burden of disease.